Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Vasc Interv Radiol ; 35(2): 285-292, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37871832

RESUMEN

PURPOSE: To determine whether inhibition of the F11 receptor/JAM-A (F11R) using F11R-specific antagonist peptide 4D results in inhibition of smooth muscle cell (SMC) proliferation and migration in vivo, known as neointimal hyperplasia (NIH), using a mouse focal carotid artery stenosis model (FCASM). MATERIALS AND METHODS: The mouse FCASM was chosen to test the hypothesis because the dominant cell type at the site of stenosis is SMC, similar to that in vascular access stenosis. Fourteen C57BL/6 mice underwent left carotid artery (LCA) partial ligation to induce stenosis, followed by daily injection of peptide 4D in 7 mice and saline in the remaining 7 mice, and these mice were observed for 21 days and then euthanized. Bilateral carotid arteries were excised for histologic analysis of the intima and media areas. RESULTS: The mean intimal area was significantly larger in control mice compared with peptide 4D-treated mice (0.031 mm2 [SD ± 0.024] vs 0.0082 mm2 [SD ± 0.0103]; P = .011). The mean intima-to-intima + media area ratio was significantly larger in control mice compared with peptide 4D-treated mice (0.27 [SD ± 0.13] vs 0.089 [SD ± 0.081]; P = .0079). NIH was not observed in the right carotid arteries in both groups. CONCLUSIONS: Peptide 4D, an F11R antagonist, significantly inhibited NIH in C57BL/6 mice in a FCASM.


Asunto(s)
Estenosis Carotídea , Molécula A de Adhesión de Unión , Animales , Ratones , Hiperplasia/metabolismo , Hiperplasia/patología , Molécula A de Adhesión de Unión/metabolismo , Túnica Íntima/patología , Modelos Animales de Enfermedad , Constricción Patológica/patología , Ratones Endogámicos C57BL , Neointima/metabolismo , Neointima/patología , Arterias Carótidas , Péptidos/farmacología , Péptidos/metabolismo
2.
Microvasc Res ; 138: 104218, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34182003

RESUMEN

BACKGROUNDS AND AIMS: To address the problem of resistance to standard antiplatelet therapy in some patients, our team proposed a purinoceptor-dependent dual therapy. Its efficacy is also determined by the condition of the vascular endothelium which, by secreting numerous factors, is involved in hemostasis. Among them, thrombospondin-1 is important in the context of thrombotic events. Therefore we sought to determine if the novel dual purinoceptor-dependent concept is associated with TSP-1 changes in vascular endothelial cells. METHODS AND RESULTS: TSP-1 expression in human microvascular endothelial cells was determined at transcriptional and protein level. We performed real-time PCR, the Western blot analysis and ELISA test. We found that TSP-1 mRNA and protein expression levels significantly changed in response to P1R agonists treatment. Furthermore, we have observed that co-administration of selective A2AR agonists (UK-432,097 or MRE0094) with P2Y12R antagonists altered TSP-1 expression levels, and the direction of these changes was not synergistic. MRE0094 applied with ARC69931MX or R-138727 increased mRNA expression from 39 to 56 or 57%, respectively (*P < 0.05 vs. MRE0094; ***P < 0.001 vs. control). Also, in the case of the P2Y12R antagonists used together with UK-432,097, there was an increase from 53 to 71 and 70% (*P < 0.05 vs. UK-432,097; ***P < 0.001 vs. control). The observed trends in gene expression were reflected in the protein expression and the level of its secretion from HMEC-1. CONCLUSION: The article presents evidence which proves that the purinoceptor-dependent concept is associated with TSP-1 changes in endothelial cells (EC). Moreover, Human Microvascular Endothelial Cells treatment applied together with agonists (MRE0094 or UK-432,097) and P2Y12R antagonist did not result in any synergistic effect, implicating a possible crosstalk between G proteins in GPCRs dependent signaling. Therefore, we suggest that understanding of the specific mechanism underlying TSP-1 alterations in EC in the context of the dual purinoceptor-dependent approach is essential for antiplatelet therapies and should be the subject of future research.


Asunto(s)
Agonistas del Receptor de Adenosina A2/farmacología , Microvasos/efectos de los fármacos , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptor de Adenosina A2A/efectos de los fármacos , Receptores Purinérgicos P2Y12/efectos de los fármacos , Trombospondina 1/metabolismo , Células Cultivadas , Regulación de la Expresión Génica , Humanos , Microvasos/metabolismo , Receptor Cross-Talk , Receptor de Adenosina A2A/metabolismo , Receptores Purinérgicos P2Y12/metabolismo , Vías Secretoras , Transducción de Señal , Trombospondina 1/genética
3.
J Cardiovasc Pharmacol ; 76(3): 349-359, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32569015

RESUMEN

In the recent years, the awareness of the role purinergic signaling plays as a therapeutic target has increased considerably. The purinoceptor allows the action of extracellular nucleotides (P2 receptors) and intermediary products of their metabolism, such as adenosine (P1 receptors), regulating pivotal processes occurring in the cardiovascular system. This study focuses on a dual purinoreceptor-dependent approach, based on the activation of adenosine P1 receptors with the simultaneous inhibition of P2Y12 receptors that can be used as novel platelet inhibitors in antithrombotic therapy. Endothelial cells are directly exposed to the drugs circulating in the bloodstream. That is why effects of our concept on human microvascular endothelial cells (HMEC-1) were examined in in vitro studies, such as enzyme-linked immunosorbent assay and scratch assays. In response to adenosine receptor agonists, levels of secreted vascular endothelial growth factor varied. Two of them, 5'-N-ethylcarboxamidoadenosine and MRE0094 remarkably increased vascular endothelial growth factor release. The elevated levels were reduced when used together with the P2Y12 receptor antagonist. Also, rates of wound closure in a scratch assay were significantly reduced in these cases. The results suggest that the proposed treatment does not impair endothelial cell condition. In addition, it is suggested as a collateral benefit, namely solving the problem of excessive activation of endothelial cells during antiplatelet therapy.


Asunto(s)
Células Endoteliales/efectos de los fármacos , Microvasos/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Agonistas del Receptor Purinérgico P1/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Purinérgicos P1/efectos de los fármacos , Receptores Purinérgicos P2Y12/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismo , Línea Celular , Movimiento Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Terapia Antiplaquetaria Doble , Células Endoteliales/metabolismo , Células Endoteliales/patología , Humanos , Masculino , Microvasos/metabolismo , Microvasos/patología , Receptores Purinérgicos P1/metabolismo , Receptores Purinérgicos P2Y12/metabolismo , Vías Secretoras , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA